143 related articles for article (PubMed ID: 30153359)
1. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Muir AJ; Levy C; Janssen HLA; Montano-Loza AJ; Shiffman ML; Caldwell S; Luketic V; Ding D; Jia C; McColgan BJ; McHutchison JG; Mani Subramanian G; Myers RP; Manns M; Chapman R; Afdhal NH; Goodman Z; Eksteen B; Bowlus CL;
Hepatology; 2019 Feb; 69(2):684-698. PubMed ID: 30153359
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Hatami B; Mosala M; Hassani AH; Ardakani MJE; Gholami S; Zali MR
Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
[TBL] [Abstract][Full Text] [Related]
3. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.
Tabibian JH; Gossard A; El-Youssef M; Eaton JE; Petz J; Jorgensen R; Enders FB; Tabibian A; Lindor KD
Am J Ther; 2017; 24(1):e56-e63. PubMed ID: 24914504
[TBL] [Abstract][Full Text] [Related]
4. Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.
Hirschfield GM; Arndtz K; Kirkham A; Chen YY; Fox R; Rowe A; Douglas-Pugh J; Thorburn D; Barnes E; Aithal GP; Hull D; Bhandal K; Olsen K; Woodward P; Lax S; Newsome P; Smith DJ; Kallio A; Adams DH; Homer V; Weston CJ
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668724
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review.
Russo MW
World J Hepatol; 2023 Sep; 15(9):1013-1020. PubMed ID: 37900215
[TBL] [Abstract][Full Text] [Related]
6. Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials.
Li M; Pai RA; Gomel R; Vyas M; Callif SC; Hatchett J; Bowlus CL; Lai JC
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727680
[TBL] [Abstract][Full Text] [Related]
7. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
8. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
9. Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.
Tabibian JH; Ali AH; Lindor KD
Gastroenterol Hepatol (N Y); 2018 Jul; 14(7):427-432. PubMed ID: 30166959
[TBL] [Abstract][Full Text] [Related]
10. Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise?
Ma C; Kotze PG
Aliment Pharmacol Ther; 2018 Sep; 48(5):576-577. PubMed ID: 30156325
[No Abstract] [Full Text] [Related]
11. Is This the Last Requiem for Simtuzumab?
Fickert P
Hepatology; 2019 Feb; 69(2):476-479. PubMed ID: 30303551
[No Abstract] [Full Text] [Related]
12. Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Sep; 48(5):578-579. PubMed ID: 30156321
[No Abstract] [Full Text] [Related]
13. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase (LOX) limits VSMC proliferation and neointimal thickening through its extracellular enzymatic activity.
Varona S; Orriols M; Galán M; Guadall A; Cañes L; Aguiló S; Sirvent M; Martínez-González J; Rodríguez C
Sci Rep; 2018 Sep; 8(1):13258. PubMed ID: 30185869
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate in Primary Biliary Cholangitis.
Corpechot C; Chazouillères O; Rousseau A
N Engl J Med; 2018 Sep; 379(10):985. PubMed ID: 30184460
[No Abstract] [Full Text] [Related]
16. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
Goode EC; Clark AB; Mells GF; Srivastava B; Spiess K; Gelson WTH; Trivedi PJ; Lynch KD; Castren E; Vesterhus MN; Karlsen TH; Ji SG; Anderson CA; Thorburn D; Hudson M; Heneghan MA; Aldersley MA; Bathgate A; Sandford RN; Alexander GJ; Chapman RW; Walmsley M; ; Hirschfield GM; Rushbrook SM
Hepatology; 2019 May; 69(5):2120-2135. PubMed ID: 30566748
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial.
Allegretti JR; Kassam Z; Carrellas M; Mullish BH; Marchesi JR; Pechlivanis A; Smith M; Gerardin Y; Timberlake S; Pratt DS; Korzenik JR
Am J Gastroenterol; 2019 Jul; 114(7):1071-1079. PubMed ID: 30730351
[TBL] [Abstract][Full Text] [Related]
20. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
